Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Click to increase image sizeClick to decrease image size AcknowledgementsDSW and PMB analyzed the data and wrote the paper. CR and AB analyzed the data, provided statistical support, and contributed to the paper. BTH, CC, PMR, AW, RK, JNW, LEO, AB, PS, HPM, MSW, JWF, SH, and PMB conducted the research, reviewed, and contributed to the paper.Disclosure statementDSW, AMB, JWF and JNW report no conflicts of interest.BTH: Research funding and consulting fees from Genentech, Abbvie, and TG TheraueticsCC: Research funding from SecuraBio, Gilead, Genentech, and BMSPMR: research funding from Roche/Genentech, consulting for Kite Pharma/Gilead and Caribou BiosciencesAW: consulting for Seattle Genetics, Janssen, AstraZeneca and ADC Therapeutics.RK: Advisory Board for BMS, Gilead Sciences/Kite Pharma, Janssen, Pharmacyclics, Morphosys, Genentech/Roche, Calithera, Miltenyi, Lilly Oncology. Research Support: BMS, Takeda, BeiGene, Gilead Sciences/Kite, Calithera. Speakers Bureau: AstraZeneca, BeiGene, MorphosysLIG: DSMB Janssen. Advisory Board: BMS and Kite. Co-founder: Zylem, Inc. Consulting: Ono PharmaceuticalsSM; Speaker: Astrazeneca, Beigene, Janssen, Lilly, Pharmacyclics. Advisory board/consulting: Abbvie, Astrazeneca, Beigene, BMS, Genentech, Janssen, Pharmacyclics TG therapeuticsResearch funding: Abbvie, Astrazeneca, Beigene, Juno, Janssen, Loxo, TG therapeutics.PMB: Consulting for Abbvie/PCYC, Beigene, Gilead, BMS/Celgene, AstraZeneca, TG, Janssen, Regeneron, Seattle Genetics, Merck, Morphosys, AdaptiveCR, AB, PS, HPM, MSW report employment by TG TherapeuticsAdditional informationFundingFunding for this trial was provided by TG Therapeutics.